vepesid 50 mg capsule, soft
bristol-myers squibb pharmaceuticals uc - etoposide - capsule - 50 mg milligram(s) - podophyllotoxin derivatives; etoposide
orencia 250 mg
bristol, myers squibb (israel) limited, israel - abatacept - powder for concentrate for solution for infusion - abatacept 250 mg - abatacept - abatacept - orencia is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. orencia may be used as monotherapy or concomitantly with disease-modifying antirheumatic drugs (dmards) other than tumor necrosis factor (tnf) antagonists. polyarticular juvenile idiopathic arthritis: orencia in combination with methotrexate is indicated for the treatment of moderate to severe active polyarticular juvenile idiopathic arthritis (jia) in paediatric patients 6 years of age and older who have had an insufficient response to other dmards including at least one tnf inhibitor. orencia has not been studied in children under 6 years old.orencia is indicated for the treatment of adult patients with active psoriatic arthritis (psa).orencia is indicated for the prophylaxis of acute graft versus host disease (agvhd), in combination with a calcineurin inhibitor and methotrexate, in adults and pediatric patients 6 years of age or older undergoing hematopoietic stem cell transplantation (hsct) from a matched or 1 allele-mismatched unrelated-donor.
orencia 125 mg sc
bristol, myers squibb (israel) limited, israel - abatacept - solution for injection - abatacept 125 mg/ml - abatacept - abatacept - orencia is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. orencia may be used as monotherapy or concomitantly with disease-modifying antirheumatic drugs (dmards) other than tumor necrosis factor (tnf) antagonists.orencia is indicated for the treatment of adult patients with active psoriatic arthritis (psa).
baraclude 0.05mgml oral solution
bristol-myers squibb pharmaceuticals ltd - entecavir monohydrate - oral solution - 50microgram/1ml
half capozide
bristol-myers squibb pharmaceuticals ltd - captopril hydrochlorothiazide - tablets - 25/12.5 milligram
half capozide 25/12.5 milligram tablets
bristol-myers squibb pharmaceuticals ltd - captopril hydrochlorothiazide - tablets - 25/12.5 milligram
adcortyl in orabase 0.1% w/w oromucosal paste
bristol-myers squibb pharmaceuticals ltd - triamcinolone acetonide - oromucosal paste - 0.1 %w/w
capoten 12.5 mg tablets
bristol-myers squibb pharmaceuticals ltd - captopril - tablets - 12.5 milligram
graneodin ointment
bristol-myers squibb pharmaceuticals ltd - neomycin sulfate gramicidin - ointment - 0.25 %w/w
kenacomb cream
bristol-myers squibb pharmaceuticals ltd - triamcinolone acetonide nystatin neomycin sulfate gramicidin - cream - 15 grams